Cancer Immunology, Immunotherapy

, Volume 54, Issue 4, pp 400–406

Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma

  • Matthias Wölfl
  • Achim A. Jungbluth
  • Federico Garrido
  • Teresa Cabrera
  • Sharon Meyen-Southard
  • Rüdiger Spitz
  • Karen Ernestus
  • Frank Berthold
Short Communication

DOI: 10.1007/s00262-004-0603-z

Cite this article as:
Wölfl, M., Jungbluth, A.A., Garrido, F. et al. Cancer Immunol Immunother (2005) 54: 400. doi:10.1007/s00262-004-0603-z

Abstract

Background: Neuroblastoma is the most common solid extracranial tumor in childhood, still with poor survival rates for metastatic disease. Neuroblastoma cells are of neuroectodermal origin and express a number of cancer germline (CG) antigens. These CG antigens may represent a potential target for immunotherapy such as peptide-based vaccination strategies. Objective: The purpose of this study was to analyze the presence of MAGE-A1, MAGE-A3/A6, and NY-ESO-1 on an mRNA and protein level and to determine the expression of MHC class I and MHC class II antigens within the same tumor specimens. Methods: A total of 68 tumors were available for RT-PCR, and 19/68 tumors were available for immunohistochemical (IHC) analysis of MAGE-A1, MAGE-A3/A6, and NY-ESO-1. In parallel, the same tumors were stained with a panel of antibodies for MHC class I and MHC class II molecules. Results: Screening of 68 tumor specimens by RT-PCR revealed expression of MAGE-A1 in 44%, MAGE-A3/A6 in 21%, and NY-ESO-1 in 28% of cases. Immunohistochemistry for CG antigens of selected tumors showed good agreement between protein and gene expression. However, staining revealed a heterogeneous expression of CG antigens. None of the selected tumors showed MHC class I or MHC class II expression. Conclusions: mRNA expression of MAGE-A1, MAGE-A3/A6, and NY-ESO-1 is congruent with the protein expression as determined by immunohistochemistry. The heterogeneous CG-antigen expression and the lack of MHC class I and II molecules may have implications for T-cell–mediated immunotherapy in neuroblastoma.

Keywords

Cancer germline antigens Immunotherapy MAGE MHC expression Neuroblastoma NY-ESO-1 

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Matthias Wölfl
    • 1
    • 4
  • Achim A. Jungbluth
    • 2
  • Federico Garrido
    • 3
  • Teresa Cabrera
    • 3
  • Sharon Meyen-Southard
    • 1
  • Rüdiger Spitz
    • 1
  • Karen Ernestus
    • 1
  • Frank Berthold
    • 1
  1. 1.Children’s Hospital, Department of Pediatric Hematology and OncologyUniversity of CologneCologneGermany
  2. 2.Ludwig Institute for Cancer Research at Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Departamento de Analisis ClinicosHospital Universitario Virgen des las NievesGranadaSpain
  4. 4.Program in ImmunologyFred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations